Ovarian Cancer | Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

published 1 month ago by Dr Neil Love

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Susana Banerjee, Richard T Penson and Shannon Westin, including the following topics: Introduction (0:00) Case: A woman in her late 60s with recurrent serous papillary adenocarcinoma of the fallopian tube with a germline BRCA1 mutation — Yanjun Ma, MD (5:24) Case: A woman in her mid-60s with Stage IIIC fallopian tube carcinoma with no deleterious mutations — Lyndsay J Willmott, MD (9:11) Case: A woman in her late 70s with ovarian cancer (OC) and a germline BRCA2 mutation — Shachar Peles, MD (14:22) Case: A woman in her mid-40s with Stage IIIC serous OC and a germline BRCA1 mutation — Dr Wilmott (17:06) PARP inhibitor maintenance therapy (23:32) Case: A woman in her late 60s with Stage IV OC and a germline BRCA1 mutation — Laurie Matt-Amaral, MD, MPH (39:43) Case: A woman in her late 70s with Stage IIIC OC with a germline BRCA mutation who develops anemia on olaparib — Sulfi Ibrahim, MD (43:55) Niraparib-associated thrombocytopenia and surgical procedures — Heidi E Godoy, DO (47:14) Case: A woman in her mid-70s with recurrent OC and a germline and somatic BRCA2 mutation — Dana M Chase, MD (50:42) Novel strategies with PARP inhibitors in OC (53:38) CME information and select publications

more episodes from Research To Practice | Oncology Videos